Ownership of Ellab will be transferred to Novo Holdings in a move designed to boost opportunities for growth and expansion into the biotech and biopharma markets.
The move to Novo Holdings aligns with Ellab's goals of improving health and sustainability. As a leading investor in life sciences, Novo Holdings manages a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private equity assets.
Through the acquisition, Ellab will benefit from Novo Holdings' expertise and resources to provide top-notch validation, monitoring, and calibration solutions and services – with the aim of becoming a go-to partner in the biotech and pharmaceutical industry, providing high-quality tools and GMP consulting to ensure compliance and operational excellence.
By expanding its presence and capabilities in the biotech and biopharma sectors, Ellab can offer tailored solutions which enable companies to achieve their goals while maintaining the highest standards of quality and compliance.
Whilst embracing new opportunities, Ellab remains committed to delivering precise and reliable validation and monitoring solutions to customers from across the pharmaceuticals, healthcare, food and beverage, medical devices, and logistics sectors.
Visit the Ellab website at https://www.ellab.com/
